Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Raytheon Technologies Corp — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Raytheon Technologies Corp trades at $187.25 (market cap $246.67B). The key difference: Raytheon Technologies Corp is far larger — about 7.9× GE HealthCare Technologies Inc. Common Stock's market cap, and Raytheon Technologies Corp pays the higher dividend (1.6%). Which is the better fit depends on your goals.
| GEHC | RTX | |
|---|---|---|
Market Cap | $31.07B | $246.67B |
Volume | 3,443,020 | 4,726,714 |
Sector | Health | Industrials |
52-Week High | $88.16 | $225.49 |
52-Week Low | $59.48 | $157.00 |
Enterprise Value | $39.53B | $277.22B |
Dividend Yield | 0.23% | 1.6% |
Typical Hold Time | — | 78 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
RTX trades at $186.66, up 0.37% on the day, with a bearish technical signal but strong fundamental momentum. The company reported revenue of $88.60 billion in 2025, with net income of $6.73 billion and a profit margin of 7.59%. Recent earnings beats and a $289 billion backlog highlight robust demand in aerospace and defense. Analyst consensus is bullish with a $233.55 price target, though technical indicators show near-term resistance.
The outlook for RTX is positive, driven by sustained defense spending and commercial aviation recovery. Investment opportunities include earnings growth and dividend yield, while risks involve execution on the large backlog and potential defense budget fluctuations. The stock offers value if it can maintain its growth trajectory amid geopolitical tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
